Virulence Factor, dupA Test

If you have tested positive for Helicobacter pylori, the next question worth asking is which kind. Not every H. pylori strain behaves the same way. Some quietly colonize the stomach for decades. Others drive aggressive inflammation, ulcers, and changes that raise long-term risk. The dupA (duodenal ulcer-promoting gene A) virulence factor is one of the strain-level markers researchers use to tell those infections apart.

This stool test detects whether the H. pylori in your gut carries dupA, a gene linked in many studies to a higher risk of duodenal ulcer and erosive gastritis, and in some populations to a lower risk of gastric cancer. The result is binary: dupA is present in your strain, or it is not. It is not a level that goes up or down with diet, supplements, or daily habits.

What dupA Actually Is

dupA is a bacterial gene, not a human protein or hormone. It sits in a region of the H. pylori genome called the plasticity zone and is thought to encode part of a type IV secretion system, a tiny molecular syringe that bacteria use to inject signals into the cells lining your stomach. When dupA is present and intact, this system can push host cells to release inflammatory messengers like IL-8 (interleukin-8) and IL-12 (interleukin-12), driving the kind of stomach inflammation that favors ulcers in the duodenum, the first segment of the small intestine just past the stomach.

Because dupA is part of the bacterium, only people infected with H. pylori can have a positive dupA result. The test does not measure something your body makes. It measures a feature of the bug. That makes it a research-tier strain marker rather than a quantitative biomarker like cholesterol or blood sugar.

Why Strain Matters

H. pylori infects roughly half of all adults worldwide, but only a fraction develop ulcers, and a smaller fraction develop stomach cancer. The reason that risk is so unevenly distributed comes down partly to which virulence genes the bacterium carries. dupA is one of the most studied of those genes. Knowing whether your strain carries it adds a layer of resolution beyond a simple positive or negative H. pylori result.

Duodenal Ulcer Risk

The most consistent finding across the dupA literature is a link with duodenal ulcer. A meta-analysis pooling data from multiple countries found that strains carrying dupA were associated with a modest increase in duodenal ulcer risk, with the strongest effects reported in Asian populations. Studies in North India and South-east India both identified dupA as a meaningful marker for duodenal ulcer in those groups, and a Chinese study of 360 patients found dupA was most prevalent in people with duodenal ulcer compared with other gastric conditions.

The mechanism fits the pattern: dupA-positive infections tend to drive antral-predominant gastritis (inflammation concentrated at the lower part of the stomach), more acid secretion, and less corpus atrophy (less wearing-down of the upper stomach lining). That combination tilts the biology toward duodenal ulcers rather than slow precancerous changes.

Gastric Cancer: A Counterintuitive Pattern

Here the evidence pulls in an unexpected direction. Several studies and reviews have found that dupA-positive strains are not consistently linked to gastric cancer, and in some regions, particularly Brazil and parts of South America, dupA-negative strains appear more often in people with gastric ulcer or gastric cancer. A microbiome study found dupA-positive strains were enriched in erosive gastritis but largely absent from precancerous lesions.

This is not a contradiction. dupA is a phenotype indicator, not a simple risk dial. Different H. pylori phenotypes drive different downstream diseases. The same strain features that make dupA-positive infections more likely to cause duodenal ulcers, more acid, more antral inflammation, less corpus atrophy, may actually steer the stomach away from the slow, low-acid environment that favors gastric cancer over decades. So a dupA-positive result is not automatically worse, and a dupA-negative result is not automatically better. The clinical meaning depends on which disease you are trying to prevent.

Erosive Gastritis

Beyond ulcers, dupA-positive strains have been linked specifically to erosive gastritis, a pattern of stomach lining damage that sits between bland inflammation and full-blown ulceration. In a study of 48 patients, high dupA expression was associated with increased risk of erosive gastritis and, interestingly, less disturbance of the broader gastric microbiome. This positions dupA as a marker oriented toward inflammatory and ulcerative pathways rather than carcinogenic ones.

Eradication and Antibiotic Resistance

One review noted that dupA may independently raise the risk of H. pylori eradication failure, meaning standard antibiotic regimens can be less likely to clear the infection. A separate study of Iranian patients with duodenal ulcer also identified dupA-positive strains alongside clarithromycin resistance, suggesting that strain genetics and treatment response can travel together. If your test returns dupA-positive, that is one more reason to pair it with antibiotic resistance testing before starting eradication therapy.

Geographic Variation Is Significant

dupA prevalence varies dramatically by region. Global adult prevalence sits around 48 percent overall, but is extremely high in Brazil and South Africa and notably lower in parts of East Asia. Even more importantly, the clinical association of dupA with disease shifts by population. In Brazilian cohorts, dupA-positive strains show no clear link to gastroduodenal diseases at all. In Asian cohorts, the duodenal ulcer link is more consistent. This is not a marker that means the same thing everywhere.

What Counts as a Result

There are no standardized clinical reference ranges for dupA. The test reports presence or absence of the gene in the H. pylori detected in your stool sample. Research has further refined this binary by looking at intact dupA clusters, truncated forms, and specific conserved segments such as a 112-bp region linked to higher duodenal ulcer risk, but most clinical labs simply report dupA as positive or negative.

• dupA not detected: either you do not have an active H. pylori infection, or the strain you carry does not have this virulence gene.
• dupA detected: your H. pylori strain carries the duodenal ulcer-promoting gene A. In most populations studied, this is associated with higher risk of duodenal ulcer and erosive gastritis.

Because this is a Tier 3 research marker, no single result should drive a clinical decision in isolation. Interpret it together with a confirmed H. pylori positive result, your symptoms, and other virulence factors like cagA and vacA when available.

Tracking Over Time

dupA is unusual among biomarkers because it does not really move on its own. The gene either is or is not part of the H. pylori strain colonizing your gut. The only way the result genuinely changes is if your H. pylori is eradicated through treatment. After successful eradication, both H. pylori and any associated dupA signal should disappear from your stool.

That makes serial testing useful in two specific situations. The first is confirming eradication: retesting four to eight weeks after finishing antibiotics is the standard window for verifying that the infection cleared. The second is reinfection surveillance: if you previously eradicated H. pylori and want to know whether a new infection has set in, retesting can catch it. Most direct-access labs recommend at least annual GI-focused testing if you have a personal or family history of ulcers, gastric cancer, or chronic dyspepsia.

When Results Can Be Misleading

Several factors can produce confusing results.

• Recent antibiotic use: if you took antibiotics in the previous four weeks for any reason, H. pylori levels in stool may be temporarily suppressed below the detection threshold, which would make dupA testing fall negative even if the strain is still there.
• Proton pump inhibitors: PPIs (proton pump inhibitors, drugs like omeprazole and esomeprazole that suppress stomach acid) can also reduce H. pylori shedding into stool. Most labs recommend stopping PPIs for at least two weeks before stool testing for H. pylori.
• Sampling and detection limits: dupA testing depends on detecting H. pylori DNA in stool. If bacterial load is very low, the test may report dupA-negative simply because there was not enough H. pylori material to genotype, not because the strain truly lacks the gene.
• Strain heterogeneity: truncated or non-functional dupA copies may still register as dupA-positive on PCR even though the protein is not actually being made. This is one reason research increasingly looks at intact dupA clusters rather than dupA alone.

What to Do With an Abnormal Result

A dupA-positive result is most useful when interpreted alongside a full H. pylori virulence profile. The decision pathway depends on what else you find.

• dupA-positive plus active H. pylori with symptoms: worth pursuing eradication therapy, ideally guided by antibiotic resistance testing for clarithromycin and fluoroquinolones since dupA may track with treatment failure.
• dupA-positive plus active H. pylori without symptoms: discuss with a gastroenterologist whether to treat. Personal or family history of ulcers, gastric cancer, or chronic NSAID (nonsteroidal anti-inflammatory drug) use should lower the threshold for treatment.
• dupA-positive after presumed successful eradication: suggests the infection was not fully cleared. Repeat testing and consider a different antibiotic regimen.
• dupA-negative with positive H. pylori: does not rule out disease risk. Other virulence factors, especially cagA and vacA s1/m1 genotypes, can still drive significant disease. Consider testing those alongside dupA.